Ra Capital Management, L.P. Vaxcyte, Inc. Transaction History
Ra Capital Management, L.P.
- $7.17 Billion
- Q3 2024
A detailed history of Ra Capital Management, L.P. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Ra Capital Management, L.P. holds 8,689,190 shares of PCVX stock, worth $749 Million. This represents 13.83% of its overall portfolio holdings.
Number of Shares
8,689,190
Previous 8,203,754
5.92%
Holding current value
$749 Million
Previous $619 Million
60.15%
% of portfolio
13.83%
Previous 9.34%
Shares
14 transactions
Others Institutions Holding PCVX
# of Institutions
353Shares Held
122MCall Options Held
775KPut Options Held
433K-
Vanguard Group Inc Valley Forge, PA11.4MShares$986 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.9MShares$942 Million0.67% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$857 Million0.02% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.9MShares$422 Million0.12% of portfolio
-
Wellington Management Group LLP Boston, MA4.51MShares$389 Million0.09% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $5.11B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...